Journal
NEUROLOGY
Volume 56, Issue 11, Pages 1514-1522Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.56.11.1514
Keywords
-
Categories
Funding
- NCRR NIH HHS [MO1-RR00585] Funding Source: Medline
- NEI NIH HHS [U10 EY 1093-01] Funding Source: Medline
Ask authors/readers for more resources
Objective: To determine whether TV immunoglobulin (Mg) reverses chronic visual impairment in MS patients with optic neuritis (ON). Methods: In this double-blind, placebo-controlled Phase Il trial, 55 patients with persistent acuity loss after ON were randomized to receive either Mg 0.4 g/kg daily for 5 days followed by three single infusions monthly for 3 months, or placebo. Results: The trial was terminated by the National Eye Institute because of negative results when 55 of the planned 60 patients had been enrolled. Fifty-two patients completed the scheduled infusions, and 58 patients completed 12 months of follow-up. Analysis of this data indicated that a difference between treatment groups was not observed for the primary outcome measure, improvement in logMAR visual scores at 6 months (p = 0.766). Exploratory secondary analyses suggested that Mg treatment was associated with improvement in visual function (including logMAR visual scores at 6 months and visual fields at 6 and 12 months) in patients with clinically stable MS during the trial. Conclusions: Mg administration does not reverse persistent visual loss from ON to a degree that merits general use.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available